Company intelligence / Profile preview
K Pharma, Inc.
Minato-ku, Tokyo, Japanen.kpharma.co.jp ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
K Pharma is a Japanese biotech company spun out from Keio University School of Medicine. It specializes in iPS cell-based drug discovery and regenerative medicine targeting CNS disorders. The company has completed a successful Phase 1/2a trial for an iPS-derived therapy in ALS with plans to advance to Phase 3. Additional programs target spinal cord injuries and cerebral infarctions using both small molecule drugs identified via iPS models and direct regenerative approaches.
- Therapeutic areas
- Neurology
- Modalities
- Induced pluripotent stem (iPS) cell-based therapiesSmall moleculesRegenerative medicine products
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
AlfresaKeio University School of Medicine
Beyond the preview
Go deeper on K Pharma, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on K Pharma, Inc..